Assassination Plot Raises TERRIFYING Questions

Federal authorities stand accused of deliberately concealing the psychiatric drug history of a trans-identified individual who threatened President Trump’s life, raising alarming questions about what law enforcement doesn’t want the public to know.

Story Snapshot

Phillip Wharton, a trans-identified individual, posted explicit threats to kill President Trump on X.com in August 2025, including a disturbing promise to wear his face as a mask
Despite court-mandated mental health evaluations and admission of illicit drug use, no psychiatric medication records or evaluation results have been publicly disclosed
Advocacy group AbleChild alleges this concealment follows a pattern protecting the psychiatric and behavioral health industries in cases involving mass violence and threats
The case mirrors 2024’s Trump assassination attempt by Thomas Crooks, whose mental health treatment history and potential psychiatric drug use remain undisclosed despite his father’s role managing behavioral health patients

When Social Media Threats Turn Federal

On August 11, 2025, Phillip Wharton posted a chilling message on X.com suggesting Donald Trump and Elon Musk were easy targets. Eight days later, Wharton escalated with a graphic threat describing plans to kill the President and wear his face as a mask. The US Capitol Police flagged the posts, triggering a Secret Service investigation that led to two federal charges for threatening a federal official. Yet when Wharton met with agents, he defended his statements by citing beliefs about Trump’s alleged Epstein connections, a bizarre justification that raised immediate questions about mental stability.

The Secret Service’s charging documents detailed the threats and even noted Wharton’s admission to using illicit drugs. But they contained a glaring omission: zero information about psychiatric medications or mental health treatment history. A judge released Wharton pretrial with conditions including a mental health evaluation, passport surrender, and prohibition on contacting Trump. Those evaluation results never saw daylight. HIPAA privacy protections effectively erected an impenetrable wall around any psychiatric drug prescriptions Wharton might have received, including potential hormone treatments associated with gender transition.

The Pattern Law Enforcement Won’t Acknowledge

This silence isn’t isolated. AbleChild, a nonprofit organization that has spent years investigating links between psychiatric drugs and violence, points to a disturbing pattern of concealment. The 2024 assassination attempt on Trump by Thomas Crooks in Butler, Pennsylvania, followed an identical script. Crooks’ father worked as a behavioral health care manager at Community Care Behavioral Health, a firm managing $149 million in services, specializing in crisis intervention and medication compliance monitoring. Despite these connections suggesting probable mental health treatment, authorities cremated Crooks’ body before conducting comprehensive toxicology testing for psychiatric medications.

The pattern extends beyond Trump. In the 2023 Nashville Covenant School shooting, transgender shooter Audrey Hale was prescribed Buspirone, Lexapro, and Hydroxyzine, yet the autopsy failed to conduct full psychotropic drug panels. The 2018 Parkland shooting involving Nikolas Cruz saw court files sealed to protect Henderson Behavioral Health, the vendor treating him with psychiatric drugs. In each case, the behavioral health industry emerged unscathed while crucial questions about medication side effects, withdrawal symptoms, and treatment failures went unanswered. AbleChild’s work led to landmark Tennessee legislation requiring psychotropic drug testing in mass violence cases, but implementation remains inconsistent.

The Behavioral Health Industry’s Invisible Hand

The connections between violent actors and the psychiatric establishment run deeper than prescription records. Matthew Crooks, father of the Butler shooter, spent his career assessing patients and monitoring their medications at a major behavioral health organization. His son lived with grandparents following apparent drug-related issues, yet no public accounting of Thomas Crooks’ treatment history emerged. Genesis Healthcare, where the younger Crooks worked, operates nursing facilities serving populations heavily medicated with psychotropic drugs. These institutional ties suggest insider knowledge that never materialized in official investigations.

Wharton’s upper-middle-class background adds another layer of probability to undisclosed treatment. Individuals undergoing gender transition typically receive hormone therapy and often concurrent psychiatric medications to manage dysphoria, anxiety, or depression. The admission of illicit drug use during the Secret Service interview strongly suggests a history of substance issues that would normally trigger mental health interventions. Yet authorities treating this case like dozens of others have invoked privacy protections to shield information the public deserves when assessing threats to national security and public safety.

When Privacy Protections Become Cover-Ups

HIPAA regulations were designed to protect patient privacy in routine medical care, not to conceal patterns linking failed psychiatric treatments to violence against public figures. The chair of the congressional task force investigating the Butler assassination attempt has promoted mental health legislation while simultaneously refusing to release mental health information about that shooter. This duplicity reveals the uncomfortable truth that behavioral health has become too big to scrutinize. When Eric Trump publicly slammed the FBI and Pennsylvania authorities in November 2025 for their continued silence, he captured growing frustration with investigations that produce no answers.

Wyoming legislative hearings have explored connections between psychiatric drugs and violence, while advocates push for reforms requiring disclosure in cases involving threats or actual harm to others. Blood tests often fail to detect psychotropic medications, and standard autopsy protocols frequently omit comprehensive drug panels. These gaps aren’t accidental; they reflect systemic resistance to accountability within an industry worth billions. The psychiatric and pharmaceutical establishments benefit from obscurity around treatment failures, and law enforcement agencies appear complicit in maintaining that obscurity rather than confronting uncomfortable truths about medications prescribed to millions of Americans.

The Questions That Demand Answers

Why does the Secret Service meticulously document social media threats but omit psychiatric drug histories from charging documents? Why do judges order mental health evaluations without requiring public disclosure of results in cases threatening the President’s life? Why does the FBI drag investigations past the one-year mark without producing final reports on assassination attempts? These aren’t rhetorical questions; they represent failures of transparency that corrode public trust. Wharton’s case demonstrates that whether threats come from trans-identified individuals, individuals with documented mental illness, or shooters with family ties to behavioral health firms, the outcome remains the same: silence benefiting an industry that should face scrutiny.

The American people understand common sense accountability. When someone threatens to kill the President, their complete mental health and medication history becomes relevant public information, not protected privacy. When multiple violent actors share behavioral health treatment backgrounds, investigating those connections becomes mandatory, not optional. AbleChild’s advocacy work has exposed what federal agencies refuse to acknowledge: a pattern of concealment protecting psychiatric and pharmaceutical interests over public safety. Until Congress mandates disclosure requirements that override privacy protections in violence cases, law enforcement will continue hiding psychiatric drug ties, leaving citizens vulnerable to preventable threats while an unaccountable industry escapes responsibility for its failed treatments and dangerous drugs.